TFI Login

PostHeaderIcon Indian oncology market likely to triple in 4 years

oncologyMumbai: April 1, 2010:-  The oncology market in India is expected to touch nearly Rs 3,309 crore by 2014. According to a recent Frost & Sullivan report, the cancer market is expected to grow at a compounded annual growth rate (CAGR) of 21% from 2008 to 2014. The growth will be driven by the introduction of new treatments, increasing number of patients on chemotherapy, and improved access to modern cancer therapies. The Indian oncology market stood at Rs 1,065 crore in 2008.

Deaths from lung cancer, breast cancer, ovarian cancer and pancreatic cancer are rising in India. Cancer accounts for 8% of the main causes of deaths in India.

Increased rates of incidence of various cancer types prevailing in India has created interest among various companies like BMS, Pfizer, Roche, Sanofi-Aventis, GSK, SP Corporation, Fresenius Kabi, Natco Pharma, Sun Pharma, Dr Reddy's and Biocon to focus in the oncology segment. More than 30 companies in India market drugs for cancer treatment.

Please Login to read the full article
 
Discuss this item on the forums. (0 posts)
Tobacco Facts

The tobacco industry is already paying a damage of over 250 billion US$ to all 50 states of US of A.

The Global Settlement Agreement was a first attempt at a settlement between the state attorneys general and the tobacco companies. The settlement included a payment by the companies of $365.5 million, agreement to possible Food and Drug Administration regulation under certain circumstances, and stronger warning labels and restrictions on advertising. In exchange the companies would be freed from class-action suits and litigation costs would be capped. The agreement was reworked and as a result the tobacco industry is paying nearly 250 billion US dollors in damages to all the 50 States of USA as agreed under the "Master Settlement Agreement."